Glaukos Corp GKOS

US Health Care

$166.72 ▼ -1.07% ($-1.80)

Open $166.58

Prev Close $168.52

Day Range $165.37 – $171.55

52W Range $73.16 – $184.00

Market Cap $9.83B

Beta 0.75

EPS (TTM) $-3.29

📋 Company Profile

Industry	Health Care
Country	US
Exchange	NEW YORK STOCK EXCHANGE, INC.
Currency	USD
IPO Date	2015-06-25
Shares Out.	58,980,000
Website	glaukos.com ↗
Phone	13026589200
Employees	1,094
Revenue	$185.6M
Gross Profit	$151.6M
Net Income	-$18.4M
Free Cash Flow	-$12.2M
Total Assets	$920.5M
Total Liabilities	$238.0M
Equity	$682.5M

About Glaukos Corp

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Glaukos Corp is a publicly traded company under the ticker symbol GKOS on the NEW YORK STOCK EXCHANGE, INC., operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.